178 related articles for article (PubMed ID: 38305364)
41. Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration.
Jeong GR; Jang EH; Bae JR; Jun S; Kang HC; Park CH; Shin JH; Yamamoto Y; Tanaka-Yamamoto K; Dawson VL; Dawson TM; Hur EM; Lee BD
Mol Neurodegener; 2018 Feb; 13(1):8. PubMed ID: 29439717
[TBL] [Abstract][Full Text] [Related]
42. Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.
Civiero L; Cirnaru MD; Beilina A; Rodella U; Russo I; Belluzzi E; Lobbestael E; Reyniers L; Hondhamuni G; Lewis PA; Van den Haute C; Baekelandt V; Bandopadhyay R; Bubacco L; Piccoli G; Cookson MR; Taymans JM; Greggio E
J Neurochem; 2015 Dec; 135(6):1242-56. PubMed ID: 26375402
[TBL] [Abstract][Full Text] [Related]
43. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player.
Häbig K; Walter M; Poths S; Riess O; Bonin M
Neurogenetics; 2008 May; 9(2):83-94. PubMed ID: 18097693
[TBL] [Abstract][Full Text] [Related]
44. The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A.
Rivero-Ríos P; Romo-Lozano M; Madero-Pérez J; Thomas AP; Biosa A; Greggio E; Hilfiker S
J Biol Chem; 2019 Mar; 294(13):4738-4758. PubMed ID: 30709905
[TBL] [Abstract][Full Text] [Related]
45. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
46. Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2.
Singh RK; Soliman A; Guaitoli G; Störmer E; von Zweydorf F; Dal Maso T; Oun A; Van Rillaer L; Schmidt SH; Chatterjee D; David JA; Pardon E; Schwartz TU; Knapp S; Kennedy EJ; Steyaert J; Herberg FW; Kortholt A; Gloeckner CJ; Versées W
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35217606
[TBL] [Abstract][Full Text] [Related]
47. The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human.
Mir R; Tonelli F; Lis P; Macartney T; Polinski NK; Martinez TN; Chou MY; Howden AJM; König T; Hotzy C; Milenkovic I; Brücke T; Zimprich A; Sammler E; Alessi DR
Biochem J; 2018 Jun; 475(11):1861-1883. PubMed ID: 29743203
[TBL] [Abstract][Full Text] [Related]
48. Phosphopeptide analysis reveals two discrete clusters of phosphorylation in the N-terminus and the Roc domain of the Parkinson-disease associated protein kinase LRRK2.
Gloeckner CJ; Boldt K; von Zweydorf F; Helm S; Wiesent L; Sarioglu H; Ueffing M
J Proteome Res; 2010 Apr; 9(4):1738-45. PubMed ID: 20108944
[TBL] [Abstract][Full Text] [Related]
49. Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities.
Webber PJ; Smith AD; Sen S; Renfrow MB; Mobley JA; West AB
J Mol Biol; 2011 Sep; 412(1):94-110. PubMed ID: 21806997
[TBL] [Abstract][Full Text] [Related]
50. GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.
Ito G; Okai T; Fujino G; Takeda K; Ichijo H; Katada T; Iwatsubo T
Biochemistry; 2007 Feb; 46(5):1380-8. PubMed ID: 17260967
[TBL] [Abstract][Full Text] [Related]
51. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.
Gandhi PN; Chen SG; Wilson-Delfosse AL
J Neurosci Res; 2009 May; 87(6):1283-95. PubMed ID: 19025767
[TBL] [Abstract][Full Text] [Related]
52. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
Nguyen AP; Moore DJ
Adv Neurobiol; 2017; 14():71-88. PubMed ID: 28353279
[TBL] [Abstract][Full Text] [Related]
53. PINK1-dependent phosphorylation of Serine111 within the SF3 motif of Rab GTPases impairs effector interactions and LRRK2-mediated phosphorylation at Threonine72.
Vieweg S; Mulholland K; Bräuning B; Kachariya N; Lai YC; Toth R; Singh PK; Volpi I; Sattler M; Groll M; Itzen A; Muqit MMK
Biochem J; 2020 May; 477(9):1651-1668. PubMed ID: 32227113
[TBL] [Abstract][Full Text] [Related]
54. ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2.
Haebig K; Gloeckner CJ; Miralles MG; Gillardon F; Schulte C; Riess O; Ueffing M; Biskup S; Bonin M
PLoS One; 2010 Oct; 5(10):e13762. PubMed ID: 21048939
[TBL] [Abstract][Full Text] [Related]
55. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ
Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358
[TBL] [Abstract][Full Text] [Related]
56. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
[TBL] [Abstract][Full Text] [Related]
57. Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.
Ito G; Utsunomiya-Tate N
Biomolecules; 2023 May; 13(5):. PubMed ID: 37238714
[TBL] [Abstract][Full Text] [Related]
58. Capturing Differences in the Regulation of LRRK2 Dynamics and Conformational States by Small Molecule Kinase Inhibitors.
Weng JH; Ma W; Wu J; Sharma PK; Silletti S; McCammon JA; Taylor S
ACS Chem Biol; 2023 Apr; 18(4):810-821. PubMed ID: 37043829
[TBL] [Abstract][Full Text] [Related]
59. Leucine-rich repeat kinase 2: relevance to Parkinson's disease.
Guo L; Wang W; Chen SG
Int J Biochem Cell Biol; 2006; 38(9):1469-75. PubMed ID: 16600664
[TBL] [Abstract][Full Text] [Related]
60. A motif within the armadillo repeat of Parkinson's-linked LRRK2 interacts with FADD to hijack the extrinsic death pathway.
Antoniou N; Vlachakis D; Memou A; Leandrou E; Valkimadi PE; Melachroinou K; Re DB; Przedborski S; Dauer WT; Stefanis L; Rideout HJ
Sci Rep; 2018 Feb; 8(1):3455. PubMed ID: 29472595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
